THE GREATER CANNABIS COMPANY, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0006 USD | 0.00% |
|
+20.00% | -33.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 661K 55.09M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | - |
| Net Debt 2022 | 233K 19.45M | Net Debt 2023 | 265K 22.05M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.9
x | P/E ratio 2023 |
-3.45
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.09% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +20.00% | ||
| Current month | -33.33% | ||
| 3 months | -14.29% | ||
| 6 months | -40.00% | ||
| Current year | -33.33% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.00
1 year
0.000.00
3 years
0.000.01
5 years
0.000.17
10 years
0.000.74
| Managers | Title | Age | Since |
|---|---|---|---|
Aitan Zacharin
CEO | Chief Executive Officer | 41 | 14/14/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Aitan Zacharin
CEO | Chief Executive Officer | 41 | 14/14/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/24/16 | 0.0006 | 0.00% | 750,000 |
| 15/24/15 | 0.0006 | -14.29% | 284,990 |
| 14/24/14 | 0.0007 | +16.67% | 532,110 |
| 13/24/13 | 0.0006 | 0.00% | 220,100 |
| 10/24/10 | 0.0006 | +20.00% | 826,182 |
Delayed Quote OTC Markets, May 16, 2024 at 10:16 pm IST
More quotes
The Greater Cannabis Company, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. The Company conducts clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Its delivery technologies use a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides needle free, intra-oral systemic drug delivery.
Sector
Internet Services
| 1st Jan change | Capi. | |
|---|---|---|
| -33.33% | 483K | |
| +34.54% | 472B | |
| +7.21% | 138B | |
| +31.54% | 98.36B | |
| +8.11% | 93.44B | |
| +58.65% | 59.13B | |
| +17.48% | 47.5B | |
| +30.27% | 39.41B | |
| +0.85% | 35.99B | |
| +15.47% | 29.22B |
- Stock Market
- Equities
- GCAN Stock